Survodutide (BI 456906): The Glucagon/GLP-1 Dual Agonist Built for the Liver
A plain-English, evidence-first look at survodutide: how its dual GLP-1/glucagon action works, what the trials show for weight and liver, and the real-world catches.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-06-13Unusually strong investigational evidence — large RCTs with biopsy-confirmed MASH endpoints and positive Phase 3 topline — with a credible glucagon-driven edge on liver fat. But unapproved, with a real GI-driven tolerability burden and pending cardiovascular outcomes.
Balanced GLP-1/glucagon dual agonist (oxyntomodulin-modelled); the glucagon arm adds energy expenditure and direct hepatic fat effects.
Discovery/candidate-selection pharmacology supports a deliberately balanced molecule with robust anti-obesity efficacy in models.
Large Phase 2 RCTs with biopsy-confirmed MASH endpoints (NEJM) and dose-finding obesity (Lancet D&E); Phase 3 SYNCHRONIZE topline positive (not yet fully peer-reviewed).
~15–19% weight loss (Phase 2) and strong biopsy-confirmed liver-histology improvement; FDA Breakthrough Therapy for MASH with fibrosis.
Short-term trial safety well-described (GI-dominant, higher discontinuation than GLP-1 mono-agonists; modest heart-rate rise); long-term/CV pending.
Late-stage / registrational (Phase 3 SYNCHRONIZE; CVOT ongoing); not yet approved.
High for short-to-mid-term weight and liver effects; long-term outcomes open.
Investigational and unapproved anywhere; genuine product exists only inside trials, so any non-trial material is unregulated.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
An investigational GLP-1/glucagon dual agonist with unusually strong evidence — large Phase 2 RCTs with biopsy-confirmed liver (MASH) endpoints and a positive Phase 3 topline — but it is unapproved, and long-term/cardiovascular outcomes are pending.
Safety snapshot
Short-term trial safety is GI-heavy (with higher discontinuation than GLP-1 mono-agonists and a modest heart-rate signal); long-term and cardiovascular safety are unknown, and genuine product exists only inside trials.
Regulatory & legality
Investigational and unapproved anywhere; any non-trial material is unregulated grey-market.
Where claims can exceed the evidence
Strong investigational signals are not the same as approval; the evidence does not transfer to unsupervised use.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
Survodutide (development code BI 456906) is one of the more interesting names in the next wave of metabolic peptides, and for once the hype rests on unusually solid ground. Where most compounds discussed in self-experimenter circles are propped up by animal data and a handful of small studies, survodutide is backed by large, randomised, placebo-controlled, biopsy-confirmed human trials published in top-tier journals like the New England Journal of Medicine [1] and the Lancet Diabetes & Endocrinology [2].
The short version: it is a once-weekly injectable that hits two receptors at once — GLP-1 and glucagon — which gives it strong appetite and weight effects plus a direct line to the liver. In phase 2 obesity work it reached roughly 15% to 19% weight loss [2], and in biopsy-confirmed MASH (the liver disease formerly called NASH) it improved liver histology in around half to nearly two-thirds of participants [1]. As of mid-2026, phase 3 SYNCHRONIZE topline data are positive [11], and it carries FDA Breakthrough Therapy designation for non-cirrhotic MASH with significant fibrosis [11].
The catch worth stating up front: survodutide is not an approved drug anywhere as of June 2026 [11], long-term cardiovascular outcome data are still pending, and gastrointestinal side effects are a genuine, dose-limiting hurdle [1][2].
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
Adipotide: The Fat-Vessel Killer That Stalled in Humans
Adipotide melts white fat by destroying the blood vessels feeding it. Striking animal data, zero human efficacy evidence, and kidney toxicity that ended its development.
AOD-9604: The Fat-Loss Peptide That Failed Its Own Trial
AOD-9604 is a growth-hormone fragment with strong fat-loss data in animals — but its pivotal human obesity trial failed, and it was never approved as a medicine.
Cagrilintide: The Amylin Analogue Behind CagriSema
A plain-English, evidence-first look at cagrilintide — the long-acting amylin analogue, its trial record, doses studied, and why it is almost never used alone.
Mazdutide: The First GLP-1/Glucagon Dual Agonist, and What the Trials Actually Show
Mazdutide is a once-weekly GLP-1/glucagon dual agonist with strong phase 3 evidence (up to ~20% weight loss) — but it is China-only and largely untested elsewhere.